- Home
- UFCS vs PVLA Comparison
UFCS vs PVLA Comparison
Compare UFCS & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | PVLA |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.2M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UFCS | PVLA |
|---|---|---|
| Price | $36.93 | $88.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $33.00 | ★ $124.25 |
| AVG Volume (30 Days) | 117.5K | ★ 259.5K |
| Earning Date | 11-04-2025 | 11-11-2025 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ 118.04 | N/A |
| EPS | ★ 4.24 | N/A |
| Revenue | ★ $1,353,781,000.00 | N/A |
| Revenue This Year | $10.11 | N/A |
| Revenue Next Year | $3.33 | N/A |
| P/E Ratio | $8.68 | ★ N/A |
| Revenue Growth | ★ 12.12 | N/A |
| 52 Week Low | $24.11 | $11.17 |
| 52 Week High | $37.84 | $106.71 |
Technical Indicators
Market Signals| Indicator | UFCS | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 45.99 |
| Support Level | $33.53 | $95.28 |
| Resistance Level | $36.87 | $100.00 |
| Average True Range (ATR) | 0.97 | 7.48 |
| MACD | -0.13 | -1.28 |
| Stochastic Oscillator | 77.73 | 10.52 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.